Antibody Conjugation of Nanoparticles as Therapeutics for Breast Cancer Treatment

International Journal of Molecular Sciences

Iván Bravo¹  Carlos Alonso-Moreno¹  Atanasio Pandiella²  Alberto Juan³  FranciscoJ. Cimas³  Alberto Ocaña³ 

[1] Centro Regional de Investigaciones Biomédicas, Unidad NanoCRIB, 02008 Albacete, Spain;Centro de Investigación del Cáncer-CSIC, IBSAL- Salamanca and CIBERONC, 37007 Salamanca, Spain;Oncología Traslacional, Unidad de Investigación del Complejo Hospitalario Universitario de Albacete, 02008 Albacete, Spain;

关键词: breast cancer;    antibody drug conjugates;    antibody conjugate nanoparticles;    nanomedicines;    targeted delivery systems;   

DOI  :  10.3390/ijms21176018

来源: DOAJ

【 摘 要 】

Breast cancer is the most common invasive tumor in women and the second leading cause of cancer-related death. Nanomedicine raises high expectations for millions of patients as it can provide better, more efficient, and affordable healthcare, and it has the potential to develop novel therapeutics for the treatment of solid tumors. In this regard, targeted therapies can be encapsulated into nanocarriers, and these nanovehicles are guided to the tumors through conjugation with antibodies—the so-called antibody-conjugated nanoparticles (ACNPs). ACNPs can preserve the chemical structure of drugs, deliver them in a controlled manner, and reduce toxicity. As certain breast cancer subtypes and indications have limited therapeutic options, this field provides hope for the future treatment of patients with difficult to treat breast cancers. In this review, we discuss the application of ACNPs for the treatment of this disease. Given the fact that ACNPs have shown clinical activity in this clinical setting, special emphasis on the role of the nanovehicles and their translation to the clinic is placed on the revision.

【 授权许可】

Unknown